FRATES JAMES M
Known title: Chief Financial OfficerCIK: 0001235598
FRATES JAMES M's purchase track record
FRATES JAMES M has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/12/2024 | AMLX | $101K | +77.1% | +47.4% | -1.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AMLX | ▼ Sell | Open Market | 9,768 | $315K | 9/10/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,042 | $35K | 9/10/2026 | View on chart |
| AMLX | ▲ Buy | Grant | 22,807 | $0 | 8/18/2026 | View on chart |
| AMLX | ▲ Buy | Grant | 95,990 | $0 | 3/5/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 7,909 | $115K | 3/2/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 3,557 | $52K | 2/2/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 3,326 | $37K | 1/6/2026 | View on chart |
| AMLX | ▼ Sell | Open Market | 10,558 | $155K | 9/30/2025 | View on chart |
| AMLX | ▼ Sell | Open Market | 10,896 | $38K | 3/31/2025 | View on chart |
| AMLX | ▲ Buy | Grant | 68,420 | $0 | 3/6/2025 | View on chart |
| AMLX | ▲ Buy | Open Market | 40,000 | $101K | 9/12/2024 | View on chart |
| AMLX | ▲ Buy | Grant | 91,180 | $0 | 4/16/2024 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,792 | $34K | 3/5/2024 | View on chart |
| AMLX | ▲ Buy | Grant | 40,000 | $0 | 2/26/2024 | View on chart |
| AMLX | ▼ Sell | Open Market | 2,716 | $44K | 1/9/2024 | View on chart |
| AMLX | ▼ Sell | Gift | 11,072 | $0 | 10/31/2023 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 18,165 | $125K | 8/23/2023 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 32,500 | $224K | 5/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 32,000 | $862K | 5/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 500 | $14K | 5/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 30,796 | $981K | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,704 | $55K | 3/16/2023 | View on chart |
| AMLX | ▲ Buy | Grant | 21,667 | $0 | 3/16/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 1,836 | $66K | 1/6/2023 | View on chart |
| AMLX | ▼ Sell | Open Market | 822 | $30K | 1/6/2023 | View on chart |
| AMLX | ▲ Buy | Option Exercise | 5,000 | $34K | 12/30/2022 | View on chart |
| AMLX | ▲ Buy | Grant | 31,667 | $0 | 1/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026
Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.
Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.